Stryker Co. (NYSE:SYK) Stock Position Lowered by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lessened its position in Stryker Co. (NYSE:SYK) by 22.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 166,767 shares of the medical technology company’s stock after selling 48,047 shares during the period. Los Angeles Capital Management LLC’s holdings in Stryker were worth $60,044,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of SYK. Assenagon Asset Management S.A. raised its stake in shares of Stryker by 15.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock worth $3,722,000 after buying an additional 1,392 shares in the last quarter. Arkadios Wealth Advisors raised its position in shares of Stryker by 23.0% during the third quarter. Arkadios Wealth Advisors now owns 732 shares of the medical technology company’s stock worth $265,000 after purchasing an additional 137 shares during the period. J.W. Cole Advisors Inc. raised its position in shares of Stryker by 23.4% during the third quarter. J.W. Cole Advisors Inc. now owns 3,932 shares of the medical technology company’s stock worth $1,420,000 after purchasing an additional 746 shares during the period. Welch Group LLC raised its position in shares of Stryker by 7.2% during the third quarter. Welch Group LLC now owns 19,105 shares of the medical technology company’s stock worth $6,902,000 after purchasing an additional 1,284 shares during the period. Finally, Forbes J M & Co. LLP raised its position in shares of Stryker by 3.6% during the third quarter. Forbes J M & Co. LLP now owns 3,648 shares of the medical technology company’s stock worth $1,318,000 after purchasing an additional 127 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

SYK has been the topic of a number of recent analyst reports. BTIG Research boosted their target price on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Wells Fargo & Company lifted their price target on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Needham & Company LLC reiterated a “buy” rating and set a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. Citigroup lifted their price target on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $422.15.

Stryker Price Performance

NYSE SYK opened at $388.11 on Tuesday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market capitalization of $148.09 billion, a PE ratio of 50.01, a P/E/G ratio of 2.93 and a beta of 0.96. The stock has a 50-day simple moving average of $378.38 and a 200 day simple moving average of $369.78.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm posted $3.46 earnings per share. Research analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.87%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.